Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 20/20 | 1.00 |
| ▸ | JAK2 | O60674 | 18/20 | 1.00 |
| ▸ | JAK1 | P23458 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2694085 | 1.00 | NTRK1 (1.00) | NTRK1JAK2JAK1 | |
| SCHEMBL2695077 | 0.97 | NTRK1 (1.00) | NTRK1JAK2 | |
| SCHEMBL2695079 | 0.97 | NTRK1 (1.00) | NTRK1JAK2 | |
| SCHEMBL29794792 | 0.97 | NTRK1 (1.00) | NTRK1JAK2 | |
| SCHEMBL2693508 | 0.90 | NTRK1 (1.00) | NTRK1JAK2 | |
| SCHEMBL2695890 | 0.90 | NTRK1 (1.00) | NTRK1JAK2 | |
| SCHEMBL2693515 | 0.90 | NTRK1 (1.00) | NTRK1JAK2 | |
| SCHEMBL4103310 | 0.90 | NTRK1 (1.00) | NTRK1JAK2 | |
| SCHEMBL18812864 | 0.90 | NTRK1 (1.00) | NTRK1JAK2 | |
| SCHEMBL2693599 | 0.88 | JAK2 (1.00) | NTRK1JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10758542-B2 | Substituted pyrazolo[l,5-a]pyrimidine compounds as Trk kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2020-09-01 | — | — | US | claimed |
| EP-2451812-B1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS TRK KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2017-11-08 | — | — | EP | claimed |
| US-8791123-B2 | Substituted pyrazolo[1,5-a]pyrimidine compounds as Trk kinase inhibitors | ARRAY BIOPHARMA, INC. (US) | 2014-07-29 | — | — | US | claimed |
| US-20120108568-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS TRK KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2012-05-03 | — | — | US | claimed |
| US-20240158756-A1 | FEEDER-BASED AND FEEDER-FREE STEM CELL CULTURE SYSTEMS FOR STRATIFIED EPITHELIAL STEM CELLS, AND USES RELATED THERETO | UNIVERSITY OF HOUSTON SYSTEM (US) | 2024-05-16 | — | — | US | disclosed |
| US-20210164055-A1 | POINT MUTATIONS IN TRK INHIBITOR-RESISTANT CANCER AND METHODS RELATING TO THE SAME | ARRAY BIOPHARMA, INC. | 2021-06-03 | — | — | US | disclosed |
| WO-2021072238-A1 | FEEDER-BASED AND FEEDER-FREE STEM CELL CULTURE SYSTEMS FOR STRATIFIED EPITHELIAL STEM CELLS, AND USES RELATED THERETO | UNIVERSITY OF HOUSTON SYSTEM (US) | 2021-04-15 | — | — | WO | disclosed |
| US-10907215-B2 | Point mutations in TRK inhibitor-resistant cancer and methods relating to the same | LOXO ONCOLOGY, INC. (US) | 2021-02-02 | — | — | US | disclosed |
| US-10758542-B2 | Substituted pyrazolo[l,5-a]pyrimidine compounds as Trk kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2020-09-01 | — | — | US | disclosed |
| US-10724102-B2 | Point mutations in TRK inhibitor-resistant cancer and methods relating to the same | LOXO ONCOLOGY, INC. (US) | 2020-07-28 | — | — | US | disclosed |
| US-10655186-B2 | Point mutations in TRK inhibitor-resistant cancer and methods relating to the same | LOXO ONCOLOGY, INC. (US) | 2020-05-19 | — | — | US | disclosed |
| US-10378068-B2 | Point mutations in TRK inhibitor-resistant cancer and methods relating to the same | LOXO ONCOLOGY, INC. (US) | 2019-08-13 | — | — | US | disclosed |
| US-9782415-B2 | Substituted pyrazolo[1,5-a]pyrimidine compounds as Trk kinase inhibitors | ARRAY BIOPHARMA, INC. (US) | 2017-10-10 | — | — | US | disclosed |
| US-20170260589-A1 | POINT MUTATIONS IN TRK INHIBITOR-RESISTANT CANCER AND METHODS RELATING TO THE SAME | ARRAY BIOPHARMA, INC. | 2017-09-14 | — | — | US | disclosed |
| US-9682979-B2 | Substituted pyrazolo [1,5-A] pyrimidine compounds as TRK kinase inhibitors | ARRAY BIOPHARMA, INC. (US) | 2017-06-20 | — | — | US | disclosed |
| US-20170119770-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS TRK KINASE INHIBITORS | ARRAY BIOPHARMA, INC. | 2017-05-04 | — | — | US | disclosed |
| US-20170114069-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS TRK KINASE INHIBITORS | ARRAY BIOPHARMA, INC. | 2017-04-27 | — | — | US | disclosed |
| US-20150031667-A1 | Substituted Pyrazolo [1,5-A] Pyrimidine Compounds as TRK Kinase Inhibitors | ARRAY BIOPHARMA, INC. | 2015-01-29 | — | — | US | disclosed |
| US-8791123-B2 | Substituted pyrazolo[1,5-a]pyrimidine compounds as Trk kinase inhibitors | ARRAY BIOPHARMA, INC. (US) | 2014-07-29 | — | — | US | disclosed |
| US-20120108568-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS TRK KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2012-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10907215-B2 | Point mutations in TRK inhibitor-resistant cancer and methods relating to the same | NTRK3, NTRK1, NTRK2 | NTRK1 2/4885JAK2 1312/4885JAK1 2351/4885 |
| US-20210164055-A1 | POINT MUTATIONS IN TRK INHIBITOR-RESISTANT CANCER AND METHODS RELATING TO THE SAME | NTRK3, NTRK1, NTRK2 | NTRK1 2/4885JAK2 1349/4885JAK1 2460/4885 |
| US-20170119770-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS TRK KINASE INHIBITORS | TXK, FRK, LTK | NTRK1 7/4885JAK2 124/4885JAK1 139/4885 |
| US-20170114069-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS TRK KINASE INHIBITORS | TXK, FRK, LTK | NTRK1 7/4885JAK2 124/4885JAK1 139/4885 |
| US-20120108568-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS TRK KINASE INHIBITORS | FRK, TXK, TNNI3K | NTRK1 8/4885JAK2 143/4885JAK1 137/4885 |
| US-20150031667-A1 | Substituted Pyrazolo [1,5-A] Pyrimidine Compounds as TRK Kinase Inhibitors | TXK, FRK, LTK | NTRK1 7/4885JAK2 124/4885JAK1 139/4885 |
| US-10655186-B2 | Point mutations in TRK inhibitor-resistant cancer and methods relating to the same | NTRK3, NTRK1, NTRK2 | NTRK1 2/4885JAK2 1349/4885JAK1 2460/4885 |
| US-10378068-B2 | Point mutations in TRK inhibitor-resistant cancer and methods relating to the same | NTRK3, NTRK1, NTRK2 | NTRK1 2/4885JAK2 1349/4885JAK1 2460/4885 |
| US-10758542-B2 | Substituted pyrazolo[l,5-a]pyrimidine compounds as Trk kinase inhibitors | LTK, TXK, FRK | NTRK1 7/4885JAK2 133/4885JAK1 196/4885 |
| US-20170260589-A1 | POINT MUTATIONS IN TRK INHIBITOR-RESISTANT CANCER AND METHODS RELATING TO THE SAME | NTRK3, NTRK1, NTRK2 | NTRK1 2/4885JAK2 1312/4885JAK1 2351/4885 |
| US-10724102-B2 | Point mutations in TRK inhibitor-resistant cancer and methods relating to the same | NTRK3, NTRK1, NTRK2 | NTRK1 2/4885JAK2 1349/4885JAK1 2460/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.